Xin Feng1, Madison K Ramsden2, Julie Negri2, Mary Grace Baker2, Spencer C Payne3, Larry Borish4, John W Steinke5. 1. Department of Otolaryngology, QiLu Hospital of Shandong University, Jinan, China. 2. Asthma and Allergic Disease Center, University of Virginia Health System, Charlottesville, Va. 3. Asthma and Allergic Disease Center, University of Virginia Health System, Charlottesville, Va; Department of Medicine, University of Virginia Health System, Charlottesville, Va; Department of Otolaryngology-Head and Neck Surgery, University of Virginia Health System, Charlottesville, Va. 4. Asthma and Allergic Disease Center, University of Virginia Health System, Charlottesville, Va; Carter Immunology Center, University of Virginia Health System, Charlottesville, Va; Department of Medicine, University of Virginia Health System, Charlottesville, Va; Department of Microbiology, University of Virginia Health System, Charlottesville, Va. 5. Asthma and Allergic Disease Center, University of Virginia Health System, Charlottesville, Va; Carter Immunology Center, University of Virginia Health System, Charlottesville, Va; Department of Medicine, University of Virginia Health System, Charlottesville, Va. Electronic address: js3ch@virginia.edu.
Abstract
BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) differs from aspirin-tolerant disease in part because of eosinophilic tissue infiltration and overexpression of arachidonic acid metabolic pathway components that lead to enhanced secretion of cysteinyl leukotrienes and prostaglandin (PG) D2 observed constitutively and paradoxically in response to aspirin and other COX inhibitors. We have previously demonstrated the capacity of IFN-γ to drive cysteinyl leukotriene expression and response. OBJECTIVE: We investigated eosinophils as a source of PGD2 production in patients with AERD. METHODS: Eosinophils were enriched from tissue and peripheral blood obtained from control subjects, patients with aspirin-tolerant disease, and patients with AERD. mRNA was extracted and evaluated for expression of hematopoietic prostaglandin D synthase (hPGDS). Expression of hPGDS protein was confirmed with Western hybridization and immunofluorescence staining. Cells were stimulated with aspirin, and secretion of PGD2 was quantified. CD34+ progenitor cells were isolated and matured into eosinophils in the presence or absence of IFN-γ and hPGDS mRNA, and PGD2 release was measured. RESULTS: Gene expression analysis revealed that eosinophils from tissue and blood of patients with AERD display increased levels of hPGDS compared with asthmatic and control samples. Western hybridization confirmed the increase in hPGDS mRNA translated to increased protein expression. Immunofluorescence confirmed mast cells and eosinophils from tissue of patients with AERD and asthma demonstrated hPGDS expression, with higher levels in eosinophils from patients with AERD. Incubation of eosinophils from blood and tissue with aspirin stimulated PGD2 release. IFN-γ-matured eosinophil progenitors showed enhanced hPGDS expression and increased levels of PGD2 release at baseline and after aspirin stimulation. CONCLUSIONS: In addition to mast cells, eosinophils represent an important source of PGD2 in patients with AERD and identify a new target for therapeutic intervention.
BACKGROUND:Aspirin-exacerbated respiratory disease (AERD) differs from aspirin-tolerant disease in part because of eosinophilic tissue infiltration and overexpression of arachidonic acid metabolic pathway components that lead to enhanced secretion of cysteinyl leukotrienes and prostaglandin (PG) D2 observed constitutively and paradoxically in response to aspirin and other COX inhibitors. We have previously demonstrated the capacity of IFN-γ to drive cysteinyl leukotriene expression and response. OBJECTIVE: We investigated eosinophils as a source of PGD2 production in patients with AERD. METHODS: Eosinophils were enriched from tissue and peripheral blood obtained from control subjects, patients with aspirin-tolerant disease, and patients with AERD. mRNA was extracted and evaluated for expression of hematopoietic prostaglandin D synthase (hPGDS). Expression of hPGDS protein was confirmed with Western hybridization and immunofluorescence staining. Cells were stimulated with aspirin, and secretion of PGD2 was quantified. CD34+ progenitor cells were isolated and matured into eosinophils in the presence or absence of IFN-γ and hPGDS mRNA, and PGD2 release was measured. RESULTS: Gene expression analysis revealed that eosinophils from tissue and blood of patients with AERD display increased levels of hPGDS compared with asthmatic and control samples. Western hybridization confirmed the increase in hPGDS mRNA translated to increased protein expression. Immunofluorescence confirmed mast cells and eosinophils from tissue of patients with AERD and asthma demonstrated hPGDS expression, with higher levels in eosinophils from patients with AERD. Incubation of eosinophils from blood and tissue with aspirin stimulated PGD2 release. IFN-γ-matured eosinophil progenitors showed enhanced hPGDS expression and increased levels of PGD2 release at baseline and after aspirin stimulation. CONCLUSIONS: In addition to mast cells, eosinophils represent an important source of PGD2 in patients with AERD and identify a new target for therapeutic intervention.
Authors: Marek Sanak; Anna Gielicz; Krzysztof Nagraba; Marek Kaszuba; Jagoda Kumik; Andrew Szczeklik Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2010-07-01 Impact factor: 3.205
Authors: John W Steinke; Lixia Liu; Phillip Huyett; Julie Negri; Spencer C Payne; Larry Borish Journal: J Allergy Clin Immunol Date: 2013-06-24 Impact factor: 10.793
Authors: B Dahlén; E Nizankowska; A Szczeklik; O Zetterström; G Bochenek; M Kumlin; L Mastalerz; G Pinis; L J Swanson; T I Boodhoo; S Wright; L M Dubé; S E Dahlén Journal: Am J Respir Crit Care Med Date: 1998-04 Impact factor: 21.405
Authors: Spencer C Payne; S Brandon Early; Phillip Huyett; Joseph K Han; Larry Borish; John W Steinke Journal: Laryngoscope Date: 2011-09-06 Impact factor: 3.325
Authors: Petra Schratl; Julia F Royer; Evi Kostenis; Trond Ulven; Eva M Sturm; Maria Waldhoer; Gerald Hoefler; Rufina Schuligoi; Irmgard Th Lippe; Bernhard A Peskar; Akos Heinemann Journal: J Immunol Date: 2007-10-01 Impact factor: 5.422
Authors: P Sestini; L Armetti; G Gambaro; M G Pieroni; R M Refini; A Sala; A Vaghi; G C Folco; S Bianco; M Robuschi Journal: Am J Respir Crit Care Med Date: 1996-02 Impact factor: 21.405
Authors: A R Fischer; M A Rosenberg; C M Lilly; J C Callery; P Rubin; J Cohn; M V White; Y Igarashi; M A Kaliner; J M Drazen Journal: J Allergy Clin Immunol Date: 1994-12 Impact factor: 10.793
Authors: Jacqueline J Eastman; Kellen J Cavagnero; Adam S Deconde; Alex S Kim; Maya R Karta; David H Broide; Bruce L Zuraw; Andrew A White; Sandra C Christiansen; Taylor A Doherty Journal: J Allergy Clin Immunol Date: 2017-03-06 Impact factor: 10.793
Authors: Kavita Pal; Madison Ramsden; Yun M Shim; Larry Borish; Spencer C Payne; John W Steinke Journal: Ann Allergy Asthma Immunol Date: 2019-09-09 Impact factor: 6.347
Authors: Jaideep Dhariwal; Aoife Cameron; Maria-Belen Trujillo-Torralbo; Ajerico Del Rosario; Eteri Bakhsoliani; Malte Paulsen; David J Jackson; Michael R Edwards; Batika M J Rana; David J Cousins; Trevor T Hansel; Sebastian L Johnston; Ross P Walton Journal: Am J Respir Crit Care Med Date: 2017-06-15 Impact factor: 21.405
Authors: Whitney W Stevens; Elina Jerschow; Alan P Baptist; Larry Borish; John V Bosso; Kathleen M Buchheit; Katherine N Cahill; Paloma Campo; Seong H Cho; Anjeni Keswani; Joshua M Levy; Anil Nanda; Tanya M Laidlaw; Andrew A White Journal: J Allergy Clin Immunol Date: 2020-12-09 Impact factor: 10.793